Matricellular proteins and survival in patients with pancreatic cancer: A systematic review

Fiorino, Sirio; Reggiani, Maria Letizia Bacchi; Birtolo, Chiara; Acquaviva, Giorgia; Visani, Michela; Fornelli, Adele; Masetti, Michele; Tura, Andrea; Sbrignadello, Stefano; Grizzi, Fabio; Patrinicola, Federica; Zanello, Matteo; Mastrangelo, Laura; Lombardi, Raffaele; Benini, Claudia; Tommaso, Luca Di; Bondi, A; Monetti, Francesco; Siopis, Elena; Orlandi, P.; Imbriani, Michele; Fabbri, Carlo; Giovanelli, S.; Domanico, Andrea; Accogli, Esterita; Saverio, Salomone Di; Grifoni, Daniela; Cennamo, Vincenzo; Leandri, Paolo; Jovine, Elio; Biase, Dario de

doi:10.1016/j.pan.2017.11.001

Cited by 7 publications

(1 citation statement)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the last years, some studies have been focused on the possible role of ECM structural and non-structural proteins in modulating the process of carcinogenesis [8] in different organs, including pancreas. In particular, several members of matricellular Protein Family, as described in the review by Joanne Murphy-Ullrich [9], have been considered and an association between their serum and/or tissue concentrations with the survival of patients, suffering from PDAC, has progressively emerged [10]. Since then, additional trials have identified and characterized different isoforms for each among the known matricellular proteins, detectable not only in the normal tissue of different organs [11], but also in cancerous lesions [12,13].…”

Section: Introductionmentioning

confidence: 99%

Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Pancreatic adenocarcinoma (PDAC) is the most frequent histological type of malignancy in the pancreas. Extracellular matrix (ECM), plays a critical role during the process of human carcinogenesis and the possible diversity in matricellular proteins composition of ECM may have a significant impact on the clinical course of PDAC. Aim of this paper was to evaluate the expression of three matricellular proteins, including Periostin (POSTN), Tenascin (TNS) and Osteopontin (OPN), in PDAC from long-survival (LS) and non-long survival (NLS) patients. A total of 30 PDAC were analyzed, 15 from patients that survived more than 60 months after surgery (LS) and 15 that died from the disease within 24 (NLS). RNA was extracted and OPN, TNS and POSTN mRNA levels were evaluated by qRT-PCR. LS and NLS samples showed the same type of POSTN and TN isoforms. On the contrary, OPN seems to be preferentially expressed in NLS PDAC. Moreover, OPNb and OPNc isoforms were expressed exclusively in NLS samples. In conclusion, Our data led to hypothesize a possible relationship between the expression of different isoforms of each of these proteins and the clinical outcome of patients with PDAC.

show abstract